These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11370994)

  • 21. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
    Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
    Jones B; Taylor CC; Meehan K
    J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
    Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine on trial.
    Mattes JA
    Am J Psychiatry; 1998 Jan; 155(1):153; author reply 153-5. PubMed ID: 9433359
    [No Abstract]   [Full Text] [Related]  

  • 33. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD; Sanger TM; Lu Y; Thieme ME
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of olanzapine: an overview of pivotal clinical trials.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex differences in clinical response to olanzapine compared with haloperidol.
    Goldstein JM; Cohen LS; Horton NJ; Lee H; Andersen S; Tohen M; Crawford A; Tollefson G
    Psychiatry Res; 2002 May; 110(1):27-37. PubMed ID: 12007591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine for primary negative symptoms.
    Licht RW
    Am J Psychiatry; 1998 Aug; 155(8):1133-4. PubMed ID: 9699711
    [No Abstract]   [Full Text] [Related]  

  • 37. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.
    Ellingrod VL; Perry PJ; Lund BC; Bever-Stille K; Fleming F; Holman TL; Miller D
    J Clin Psychopharmacol; 2002 Dec; 22(6):622-4. PubMed ID: 12454564
    [No Abstract]   [Full Text] [Related]  

  • 38. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
    Barak Y; Shamir E; Zemishlani H; Mirecki I; Toren P; Weizman R
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1199-202. PubMed ID: 12452546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
    Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.